Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial
Sarah Brown, Charlotte Pawlyn, Avie‐Lee Tillotson, Debbie Sherratt, Louise Flanagan, Eric Low, Gareth J. Morgan, Cathy Williams, Martin Kaiser, Faith E. Davies, Matthew Jenner
Topics & Concepts
VorinostatBortezomibTolerabilityMedicineDexamethasoneMultiple myelomaInternal medicineOncologyCombination therapyToxicityPharmacologyGastroenterologyHistone deacetylaseAdverse effectBiologyHistoneGeneBiochemistryHistone Deacetylase Inhibitors ResearchMultiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research